Executive Summary
Amgen seeks Director review of a denied institution for IPR2025‑00602, arguing that Bristol‑Myers Squibb’s Opdivo® flat‑dose patent is obvious and was improperly shielded by a discretionary denial based on settled expectations.
Related Cases
Samsung Electronics Co., Ltd. et al.vsNetwork-1 Technologies, Inc.
Samsung has filed an IPR petition to invalidate all 22 claims of Network‑1’s eUICC provisioning patent (US 12,207,094), asserting obviousness over multiple prior‑art references such as Park, GlobalPlatform, AbiChar, X9.63‑Overview, Weiss and Nix175.
Capital One, National Associationvs--
Capital One filed an unopposed motion to terminate IPR 2024-00878 and to keep the settlement with Implicit, LLC confidential under statutory authority. The Board is asked to treat the settlement as business confidential information and end the proceeding.
Samsung Electronics Co., Ltd. et al.vsHannibal IP LLC
The PTAB granted institution for the IPR case involving Samsung Electronics against Hannibal IP LLC regarding patent 11641661. The petitioner successfully met the reasonable likelihood of prevailing standard.
Microsoft CorporationvsToutVirtual, Inc.
Microsoft files an IPR petition challenging ToutVirtual’s 2023 ‘Virtual Systems Management’ patent, asserting that all 14 claims are obvious over a suite of prior‑art virtualization references.
Samsung Electronics Co., Ltd. et al.vsHarbor Island Dynamic, LLC
Samsung Electronics seeks Director Review of a PTAB institution decision for a deep‑trench isolation patent, arguing the Board mis‑applied Fintiv discretionary‑denial factors. The patent owner contends the panel gave insufficient weight to the upcoming district‑court trial date and related investment.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.